Neutrophil-to-lymphocyte ratio predicts the prognosis of stage II nasopharyngeal carcinoma

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30(2):114–119.21272443
   PubMedGoogle Scholar
• Guo Q, Lu T, Lin S, et al. Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era. Jpn J Clin Oncol. 2016;46(3):241–247. doi:10.1093/jjco/hyv19226755831
   PubMed Web of Science ®Google Scholar
• Kang MK, Oh D, Cho KH, et al. Role of chemotherapy in Stage II nasopharyngeal carcinoma treated with curative radiotherapy. Cancer Res Treat. 2015;47(4):871–878. doi:10.4143/crt.2014.14125687858
   PubMed Web of Science ®Google Scholar
• Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013;119(5):963–970. doi:10.1002/cncr.2785323065693
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma. Cancer. 2003;98(1):74–80. doi:10.1002/cncr.1148512833458
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000;60(24):6878–6881.11156384
   PubMed Web of Science ®Google Scholar
• Lin JC, Chen KY, Wang WY, et al. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol. 2001;19(10):2607–2615. doi:10.1200/JCO.2001.19.10.260711352952
   PubMed Web of Science ®Google Scholar
• Lin JC, Wang WY, Liang WM, et al. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(5):1342–1348. doi:10.1016/j.ijrobp.2007.02.01217449194
   PubMed Web of Science ®Google Scholar
• Shen L, Zhang H, Liang L, et al. Baseline neutrophil-lymphocyte ratio (>/=2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiat Oncol. 2014;9:295. doi:10.1186/s13014-014-0295-225518933
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27(4):732–738. doi:10.1093/annonc/mdw01626802161
   PubMed Web of Science ®Google Scholar
• Kawahara T, Yokomizo Y, Ito Y, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. BMC Cancer. 2016;16:111. doi:10.1186/s12885-016-2134-326883640
   PubMed Web of Science ®Google Scholar
• Lu A, Li H, Zheng Y, et al. Prognostic significance of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, and platelet to lymphocyte ratio in patients with nasopharyngeal carcinoma. Biomed Res Int. 2017;2017:3047802. doi:10.1155/2017/304780228321405
   PubMed Web of Science ®Google Scholar
• Chua ML, Tan SH, Kusumawidjaja G, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials. Eur J Cancer. 2016;67:119–129. doi:10.1016/j.ejca.2016.08.00627640138
   PubMed Web of Science ®Google Scholar
• Chen C, Sun P, Dai QS, Weng HW, Li HP, Ye S. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma. PLoS One. 2014;9(11):e112581. doi:10.1371/journal.pone.011258125393117
   PubMed Web of Science ®Google Scholar
• Jiang Y, Qu S, Pan X, Huang S, Zhu X. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma. Oncotarget. 2018;9(11):9992–10004. doi:10.18632/oncotarget.2417329515785
   PubMedGoogle Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-420180029
   PubMed Web of Science ®Google Scholar
• Pan XB, Chen KH, Huang ST, et al. Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma. Oncotarget. 2017;8:78096.29100451
   PubMedGoogle Scholar
• Luo S, Zhao L, Wang J, et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck. 2014;36(6):841–847. doi:10.1002/hed.2338623720240
   PubMed Web of Science ®Google Scholar
• Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009;74(4):1070–1076. doi:10.1016/j.ijrobp.2008.09.00819231110
   PubMed Web of Science ®Google Scholar
• Pan XB, Huang ST, Chen KH, Zhu XD. Chemotherapy use and survival in stage II nasopharyngeal carcinoma. Oncotarget. 2017;8(60):102573–102580. doi:10.18632/oncotarget.2175129254272
   PubMedGoogle Scholar
• Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys. 2012;82(1):327–333. doi:10.1016/j.ijrobp.2010.09.01121035959
   PubMed Web of Science ®Google Scholar
• Su Z, Mao YP, Tang J, Lan XW, OuYang PY, Xie FY. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Tumour Biol. 2016;37(4):4429–4438. doi:10.1007/s13277-015-4266-526499947
   PubMedGoogle Scholar
• Leung SF, Chan AT, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer. 2003;98(2):288–291. doi:10.1002/cncr.1149612872347
   PubMed Web of Science ®Google Scholar
• Du XJ, Tang LL, Mao YP, et al. Circulating EBV DNA, globulin and nodal size predict distant metastasis after intensity-modulated radiotherapy in Stage II nasopharyngeal carcinoma. J Cancer. 2016;7(6):664–670. doi:10.7150/jca.1418327076847
   PubMed Web of Science ®Google Scholar
• Jiang R, Cai XY, Yang ZH, et al. Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma. Chin J Cancer. 2015;34(6):237–246. doi:10.1186/s40880-015-0025-726067059
   PubMedGoogle Scholar
• Oei RW, Ye L, Kong F, et al. Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study. Cancer Manag Res. 2018;10:2785–2797. doi:10.2147/CMAR.S17123930147375
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431–446. doi:10.1038/nrc.2016.5227282249
   PubMed Web of Science ®Google Scholar
• Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504–508. doi:10.1038/clpt.2009.25420147899
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Johansson M, Coussens LM. Inflaming gastrointestinal oncogenic programming. Cancer Cell. 2008;14(1):7–9. doi:10.1016/j.ccr.2008.06.01018598939
   PubMed Web of Science ®Google Scholar
• Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2015;528(7582):413–417. doi:10.1038/nature1614026649828
   PubMed Web of Science ®Google Scholar
• Sun W, Zhang L, Luo M, et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Head Neck. 2016;38(Suppl 1):E1332–E1340. doi:10.1002/hed.2422426362911
   PubMedGoogle Scholar
• Jin Y, Ye X, He C, Zhang B, Zhang Y. Pretreatment neutrophil-to-lymphocyte ratio as predictor of survival for patients with metastatic nasopharyngeal carcinoma. Head Neck. 2015;37(1):69–75. doi:10.1002/hed.2356524327524
   PubMed Web of Science ®Google Scholar